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Heat shock proteins (Hsps) are highly conserved, and their expression is upregulated in 
cells by heat and other stressful stimuli. These proteins play a vital role in preserving the 
structural and functional integrity of cells under stress. Despite the ubiquitous expression 
of Hsps in an individual, the immune system is not fully tolerant to them. In fact, Hsps 
are highly immunogenic in nature, and immune response to these proteins is observed in 
various inflammatory and autoimmune diseases. Studies on the immunopathogenesis of 
autoimmune arthritis in the rat adjuvant arthritis (AA) model of human rheumatoid arthritis 
(RA) as well as observations in patients with RA and juvenile idiopathic arthritis (JIA) have 
unraveled immunoregulatory attributes of self-Hsp65-directed immunity. Notable fea-
tures of Hsp65 immunity in AA include protection rather than disease induction following 
immunization of Lewis rats with self (rat)-Hsp65; the diversification of T cell response 
to mycobacterial Hsp65 during the course of AA and its association with spontaneous 
induction of response to self-Hsp65; the cross-reactive T cells recognizing foreign and 
self homologs of Hsp65 and their role in disease suppression in rats; the suppressive 
effect of antibodies to Hsp65 in AA; and the use of Hsp65, its peptides, or altered 
peptide ligands in controlling autoimmune pathology. The results of studies in the AA 
model have relevance to RA and JIA. We believe that these insights into Hsp65 immunity 
would not only advance our understanding of the disease process in RA/JIA, but also 
lead to the development of novel therapeutic approaches for autoimmune arthritis.
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Adjuvant arthritis (AA) is a well-established model of human rheumatoid arthritis (RA) (1–3), 
and it has extensively been used both for studying arthritis pathogenesis and for testing new anti-
arthritic drugs. AA can be induced in inbred Lewis (RT.1l) rats by immunization with heat-killed 
Mycobacterium tuberculosis H37Ra (Mtb) (1). AA manifests as a polyarthritis after about 8–10 days 
of Mtb immunization. The disease rapidly progresses to reach a peak phase by about days 14–16, fol-
lowed by spontaneous regression of inflammation over the next 10–12 days. Following recovery, AA 
generally does not relapse or exhibit flares that are typically seen in many RA patients. In this regard, 
AA differs from RA. Mycobacterial heat shock protein 65 (Bhsp65) is one of the disease-related target 
antigens in AA (1–3). Studies on immune responses to Hsp65 have offered critical insights into 
both induction and regulation of autoimmune arthritis (3–9). Arthritic rats raise T cell response to 
Bhsp65, and the T cells directed against the epitope region 180–188 of Bhsp65 (B180) can adoptively 
FiGURe 1 | induction and regulation of adjuvant arthritis by immune 
response to Hsp65. AA can be induced in Lewis rats by subcutaneous 
immunization with heat-killed M. tuberculosis H37Ra (Mtb). Mycobacterial 
hsp65 (Bhsp5) is one of the targets of immune response in arthritic rats. The 
T cells against epitope 180–188 of Bhsp65 (B180) are pathogenic, whereas 
those against other epitopes of Bhsp65 [e.g., 256–270 (B256) and Bhsp65 
C-terminal determinants (BCTD)] are regulatory in AA. Tolerization of rats with 
soluble Bhsp65 or B180 renders these rats relatively resistant to induction of 
AA by subsequent Mtb injection. Arthritic rats also raise antibody response to 
Bhsp65, and antibodies have been shown to be protective against AA. 
Intriguingly, immunization of Lewis rats with self-Hsp65 [e.g., human Hsp60 
or rat Hsp65 (Rhsp65)] is protective rather than pathogenic. Similarly, 
induction of antibody response by a peptide of self-Hsp60 also affords 
protection against AA. Finally, challenge with altered peptide ligands (APLs) of 
Bhsp65 and self-Hsp60 can induce a disease-protective response in arthritic 
rats. Thus, immunity to Hsp65 has dual attributes: pathogenic as well as 
protective. (This figure summarizes information from multiple studies 
described in the text.)
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transfer AA to naive rats (2, 10). However, the T cells reactive 
against certain other epitopes of Bhsp65 are disease-regulating in 
nature. In our studies in AA summarized here, we have addressed 
several important questions. For example, are Lewis rats tolerant 
to self-Hsp65?; how does activation of self-Hsp65-reactive T cells 
affect the development of arthritis?; how does immune response 
to foreign Hsp65 evolve during the course of AA?; what is the 
significance of the T cell repertoire against foreign Hsp65 that 
is cross-reactive with self-Hsp65?; what role do antibodies to 
Hsp65 play in AA?; and does Hsp65 treatment influence arthritis 
induced by a non-antigenic compound? These aspects of cellular 
and humoral immunity to Hsp65 are elaborated below, based 
on results of studies by others and us. (Mammalian Hsp60 is a 
mitochondrial protein of 61 kDa, whereas Hsp65 is a mycobacte-
rial protein of 65 kDa. Hsp60 is used as a synonym for Hsp65, 
and vice versa, therefore, for simplicity, we have used Hsp60 and 
Hsp65 interchangeably in this article.)
THe ROLe OF SeLF (RAT)-HSP65 in 
ARTHRiTiS PATHOGeneSiS: iMMUne 
ReACTiviTY TO SeLF-HSP65 iS 
PROTeCTive RATHeR THAn 
PATHOGeniC
As autoimmune reactivity is generally driven by an endogenous 
self-antigen, we directed our study on AA pathogenesis to 
rat Hsp65 (Rhsp65) (9, 11). Ours was the first study to exam-
ine the state of immune tolerance to Rhsp65 in the Lewis rat. 
Surprisingly, Lewis rats were not fully tolerant to Rhsp65 (11). The 
rats challenged with Rhsp65 raised a potent response to this self-
antigen, and the pre-treatment of naive rats with Rhsp65 afforded 
protection against subsequent induction of AA by Mtb injection 
(11). These results showed that immune response to systemically 
administered self-Hsp65 is protective against arthritis instead 
of being pathogenic (Figure  1). Our studies further revealed 
that Rhsp65 C-terminal determinants (RCTD) are displayed as 
dominant epitopes following the processing and presentation of 
native Rhsp65 (11). Furthermore, peptides comprising RCTD, 
when administered into Lewis rats in a synthetic adjuvant, also 
induced a T cell response that is protective against AA (11). Thus, 
anti-self-Hsp65 immune response is protective against AA.
iMMUne ReSPOnSe TO HUMAn HSP60 
inDUCeS PROTeCTiOn AGAinST 
ARTHRiTiS in RATS
Studies using DNA vaccination approach have revealed the 
disease-regulating activity of human Hsp60 in AA (Figure  1) 
(12). Human Hsp60 was more effective than Bhsp65 in sup-
pressing AA. This protective effect was associated with increased 
interferon-γ (IFN-γ) and transforming growth factor-β (TGF-β) 
response to Hsp60, but reduced IFN-γ response to B180 (12). 
Subsequent experiments identified Hu3 as a regulatory epitope 
within human Hsp60 (13). Immunization with human Hu3, but 
not its mycobacterial homolog, was protective against AA, and 
the protective response involved both Th1 and Th2/3 cells (13). 
A cross-reactive T cell response to human Hsp60 was also invoked 
in the protective effect of DNA vaccination using Hsp70/Hsp90 
(14). Another set of studies have highlighted the role of human 
Hsp60 in activation of B cells (15), T cells (16), CD4+CD25+ 
regulatory T cells (Treg) (17), and maturation of dendritic cells 
(18), in part via Toll-like receptor 4 (TLR4) (B cells)/TLR2 (T cells 
and Treg) signaling. Furthermore, acting in a different manner, 
Hsp60 expressed on activated T cells can render them targets of 
regulatory T cells (19). In an entirely different approach based on 
CD8+ regulatory T cells instead of CD4+ regulatory T cells, it was 
shown that Hsp60(p216) peptide-specific CD8+ T cells restricted 
to a class I-like MHC molecule Qa-1 in mice (HLA-E in humans) 
effectively suppressed CIA (20). Thus, besides self-Hsp60 
epitopes recognized by CD4+ T cells, others recognized by CD8+ 
T cells may also contribute to regulation of autoimmune arthritis. 
Thus, Hsp60 can modulate both innate and adaptive immune 
response through multiple modes of action, and as for rat Hsp65, 
immunity to human Hsp60 also induced protection against AA. 
Further insights into the T cell repertoire against self-Hsp60 and 
maintenance of tolerance would help advance understanding of 
the pathogenesis of arthritis and its control (21).
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iMMUnOMODULATORY iMMUne 
ReACTiviTY TO HUMAn HSP60 in JiA 
AnD RA PATienTS
In a study on patients with JIA, the response to Hsp60 of peripheral 
blood mononuclear cells (PBMC) from oligoarticular JIA was 
compared with that of polyarticular JIA. The former group revealed 
increased expression of CD30 on T cells along with increased inter-
leukin-10 (IL-10)/IFN-γ ratio, whereas the latter group showed no 
expression of CD30 and low IL-10/IFN-γ ratio (22). Furthermore, 
remission from acute oligoarticular JIA was attributed to Hsp60-
reactive T cells. In another study, it was reported that serum human 
Hsp60 predicts remission in JIA (23). In a study on PBMC of RA 
patients, it was observed that pan-DR-binding human Hsp60 
peptides induced 5- to 10-fold higher IL-10/tumor necrosis 
factor-α (TNF-α) ratio than that by microbial peptides, indicating 
immunomodulatory activity of self-Hsp60 peptides (24). Thus, self 
(human)-Hsp60 not only induced protection against AA but also 
contributed to remission in JIA.
FOReiGn–SeLF-HSP65  
CROSS-ReACTiviTY AnD SPReADinG 
COnTROL OF ARTHRiTiS in RATS
Lewis rats treated with Bhsp65 prior to disease induction are 
protected from subsequent AA (25). Unlike Mtb-immunized 
rats, which raise T cell response predominantly to epitope 
B180, Bhsp65-treated rats raised response to multiple additional 
epitopes besides B180 (25, 26). Epitope 256–270 was among the 
nine epitopes identified upon Bhsp65 pre-treatment. The T cells 
reactive against mycobacterial 256–270 were found to be both 
cross-reactive with self counterpart (Rhsp65 256–270) as well as 
disease-regulating in nature (26). The T cells against this peptide 
could be restimulated by stressed antigen-presenting cells (APCs), 
indicating that the self-ligand recognized was processed and 
presented from endogenous Hsp60. Furthermore, the treatment 
of rats either with this peptide or with the T cells primed with it 
resulted in protection against AA (Figure 1). This cross-reactivity 
between homologous foreign and self-Hsp60 has been implicated 
in a spreading regulatory control during the course of arthritis (6). 
Self-Hsp60-reactive T cells can contribute to immune regulation 
in different ways. For example, such cells may be anergized, and 
these anergic cells mediate suppressive effects. Alternatively, self-
Hsp60 epitopes may serve as altered peptide ligands (APLs) and 
induce a regulatory response, while their corresponding microbial 
Hsp60 ligands may act as potent agonists (6). Thus, T cells acti-
vated by Bhsp65, but cross-reactive with self-Hsp65, displayed 
anti-arthritic activity against AA. 
THe DiveRSiFiCATiOn OF T CeLL 
ReSPOnSe TO BHSP65 DURinG THe 
COURSe OF AA
Rats with AA undergo spontaneous regression of inflammation. 
However, the immunological basis of this phenomenon remains 
to be fully explained. Our study revealed the diversification of 
T cell response to Bhsp65 during the course of AA (3). Arthritic 
rats in the late phase of AA displayed new T cell reactivity 
against BCTD compared to rats in early phase of the disease. 
Furthermore, synthetic peptides containing the sequences of 
BCTD, when administered into Lewis rats with a synthetic adju-
vant, induced protection against subsequent AA (3). Similarly, the 
adoptive transfer of BCTD-primed T cells reduced the severity of 
AA in recipient arthritic rats (27). Thus, deliberate priming and 
expansion of the T cells against BCTD led to protection against 
AA (Figure  1). This was the first report on regulatory epitope 
spreading in autoimmunity because an earlier report on epitope 
spreading in the EAE model described it as pathogenic (3, 28). 
Thus, our study expanded the scope of the impact of epitope 
spreading in autoimmunity and presented a framework to explain 
natural regression of inflammation in AA.
DeFininG THe MeCHAniSM OF 
SPOnTAneOUS ReGReSSiOn OF AA
We observed that BCTD represent cryptic epitopes of Bhsp65, 
meaning that these epitopes are potentially immunogenic as 
peptides, but are not efficiently revealed upon processing of the 
native foreign antigen (Bhsp65) injected into Lewis rats (27). On 
the contrary, RCTD represent the dominant epitopes of Rhsp65, 
implying that these epitopes are efficiently displayed following 
the processing and presentation of the native self-antigen admin-
istered into Lewis rats (11). Yet, BCTD can prime T cells that are 
cross-reactive with the self counterpart. We therefore explained 
regulatory epitope spreading by suggesting as well as provid-
ing evidence that inflammation accompanying acute arthritis 
upregulates Rhsp65 expression; its RCTD are then displayed to 
induce a T cell response; and these T cells can then suppress the 
progression of arthritis, as evident from adoptive transfer experi-
ments using Rhsp65- or RCTD-primed T cells (3, 11, 27, 28). We 
further suggested that inflammation also upregulates the display 
of cryptic BCTD, which then can induce T cells that cooperate 
with RCTD-primed T cells in suppressing pathogenic T cell 
response, leading to natural recovery from acute AA (Figure 1). 
Responses to BCTD are also involved in environmental modula-
tion of AA (29).
UneXPeCTeD CROSS-ReACTiviTY 
BeTween THe PATHOGeniC AnD THe 
PROTeCTive T CeLL ePiTOPeS OF 
HOMOLOGOUS HSP65 in AA
Peptide 177–191 of Bhsp65 (B177) contains the arthritogenic 
epitope B180 (2), whereas peptide 465–479 of Rhsp65 (R465) 
represents a regulatory epitope for AA (30). Immunization of 
rats with B177 in incomplete Freund’s adjuvant or CpG s.c. prior 
to Mtb injection showed marked suppression of arthritis instead 
of disease induction (30). We reasoned that the T cell subset 
activated by B177 injected in IFA/CpG is distinct from that acti-
vated by Mtb challenge; the latter subset mediates induction of 
arthritis, and that there might be some connection between B177 
FiGURe 2 | A schematic representation of the role of cross-reactive T cells directed against B180/B177 and R465 in regulation of AA. The T cells 
potentially reactive against B180/B177 of Bhsp65 (pathogenic epitope) and R465 of Rhsp65 (regulatory epitope) comprised a cross-reactive T cell subset besides 
the corresponding epitope-specific subset. The priming and expansion of these cross-reactive T cells by immunization of Lewis rats either with peptide (B180/B177 
or with R465) in adjuvant would induce protection against subsequent AA (“vaccination”). However, injection of Mtb, which contains Bhsp65, instead activates 
predominantly the B180/B177-specific pathogenic repertoire, resulting in the induction of AA. Furthermore, this pathogenic repertoire may be inactivated, or 
immune-deviated, by soluble antigen (B180/B177) administered i.p. or nasally, leading to protection against AA. This schematic figure is based on our results 
published elsewhere (3, 11, 27, 30).
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and one of the regulatory C-terminal determinants of Hsp65, 
including R465 described above. In fact, surprisingly, there was 
cross-reactivity between B177 and R465, and it involved a subset 
of T cells shared by the two epitopes (Figure 2) (30). This cross-
reactivity was further validated by tolerance induction to R465, 
which compromised B177-induced protection against AA (30). 
This is a fine example of fortuitous mimicry between a pathogenic 
Bhsp65 epitope and a regulatory Rhsp65 epitope, and it might 
represent an inbuilt mechanism of a crosstalk between such 
pairs of epitopes to mediate regression of inflammation during 
the course of autoimmunity. In retrospect, a similar mechanism 
might offer additional explanation to the observations that a T 
cell clone (A2c) recognizing B180 was protective against AA (10) 
and that soluble B180 administered intraperitoneally (i.p.) prior 
to arthritis induction can suppress the development of AA (31).
AnTiBODieS TO HSP65 ARe PROTeCTive 
RATHeR THAn PATHOGeniC in AA
Adjuvant arthritis is believed to be a T cell-mediated disease. 
Unlike T cells, antibodies of arthritic rats fail to induce AA in naive 
recipients. Instead, anti-Hsp65 antibodies can mediate protection 
against AA. It was first shown that AA-resistant rat strains possess 
antibodies that are protective against AA, whereas susceptible rat 
strains, such as Lewis, lack these antibodies (32). Accordingly, 
the transfer of antibodies of resistant strain into susceptible strain 
induced protection against AA. Subsequent studies by others (8) 
and us (33) showed that such protective antibodies also develop 
in arthritic rats after recovery from AA. During the course of AA, 
eventually the antibody response became focused on few defined 
epitopes of Bhsp65 and Rhsp65 (8, 33). Furthermore, immuniza-
tion of naive rats with specific peptide epitopes or anti-peptide 
antibodies, or sera from recovered rats, leads to protection against 
AA (Figure 1) (8, 33). The precise mechanism of protection is 
not yet fully defined, but one proposition is based on antibody-
induced IL-10 production by PBMC (8). In a recent study (34), 
a humanized monoclonal antibody against Hsp60 (Prozumab) 
was reported to display disease-suppressive activity against AA 
and CIA. This antibody also can induce IL-10 in PBMC. Thus, 
antibodies against Hsp65 in AA are disease-regulating in nature.
ReSPOnSeS TO C-TeRMinAL 
DeTeRMinAnTS OF HSP65 ARe 
invOLveD in enviROnMenTAL 
MODULATiOn OF AA
In a study on Fisher (F344) rats, whose susceptibility to arthritis 
is markedly modified by their housing environment, we showed 
that F344 rats raised in a barrier facility (BF-F344) are susceptible, 
whereas those raised in a conventional facility (CV-F344) were 
relatively resistant to AA (29). Similarly, F344 rats transferred 
from a barrier facility into a conventional facility (BF-CV-F344) 
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acquired resistance to AA in a few weeks. In simple terms, BF and 
CV are also referred to as “clean” and “dirty” housing facilities, 
with the latter providing more opportunities for animals to be 
exposed to environmental microbes. We reasoned that Hsp65 
of the environmental microbes might induce T cell response in 
CV-F344 that is cross-reactive with Bhsp65, and that these T cells 
in turn afford protection against AA. A similar situation might 
be expected for BF-F344 transferred into CV, whereas BF-344 
will be spared as they are kept in strict controlled conditions. 
To test this idea, we examined the level of T cell response to 
BCTD and other peptides of Bhsp65 in these rats without any 
immunization with Mtb or Bhsp65 (29). Interestingly, CV-F344 
spontaneously developed much higher level of T cell response 
to BCTD compared to BF-F344, whereas BF-CV-F344 were in 
between the two groups. Furthermore, adoptive transfer of spleen 
cells of CV-F344 rats, but not BF-F344 rats, reduced the severity 
of AA in recipients. Thus, BCTD-reactive T cells contribute not 
only to spontaneous regression of inflammation in Lewis rats (3) 
but also to environmental modulation of AA in F344 rats (29). 
However, the role of environmental factors on gut flora and its 
impact on AA remains to be defined.
USe OF ALTeReD PePTiDe LiGAnDS OF 
SeLF-HSP60 TO COnTROL ARTHRiTiC 
inFLAMMATiOn
We have described above the use of native Hsp65 and its peptide 
epitopes in inhibition of arthritis. APLs, with specific amino acid 
residues of the original peptide modified to affect its binding 
to the major histocompatibility complex or the T cell receptor 
leading to altered T cell response, have also been explored for 
arthritis therapy (Figure 1). Initial work involved an APL of B180 
containing alanine 183, which was shown to inhibit AA (35). It 
involved the generation of regulatory T cells and production of 
anti-inflammatory/immunomodulatory cytokines IL-4, IL-10, 
and TGF-β. Subsequently, APLs of human Hsp60 (e.g., APL-2 
and APL-1) have been shown to suppress AA/CIA (36, 37). In 
addition, APL2 increased IL-10 production, but reduced IL-17 
production by PBMC of RA patients (36), and it induced IL-10 
production in PBMC of JIA patients (37). APL-1 was reported 
to induce Foxp3+ Treg coupled with apoptosis in activated CD4+ 
T cells in PBMC of active RA patients (38).
COnCLUDinG ReMARKS
As elaborated above, studies on immune response to Hsp65 
have offered several novel insights into both the induction and 
regulation of autoimmunity (3–9). Studies in the AA model have 
revealed Bhsp65 as the target of arthritogenic T cells. However, 
Bhsp65-reactive T cells also can be disease-regulating in nature, 
and such T cells demonstrate cross-reactivity with self-Hsp65 
(3, 26). In addition, the T cells induced by self-Hsp65 also pos-
sess immunoregulatory activity against AA (11, 13) and dimethyl 
dioctadecyl ammonium bromide-induced arthritis (DIA) in 
Lewis rats (39). The regulatory role of self-Hsp65 is evident not 
only in the AA and DIA models but also in patients with JIA (22). 
On the contrary, in other disease conditions, such as diabetes (40) 
and atherosclerosis (41), pathogenic immune response has been 
shown to be directed against self-Hsp65. Nevertheless, Hsp65, its 
peptides, and APL can also be employed as immunomodulatory 
agents to attenuate these diseases. Thus, the dual role of Hsp65 has 
been reported not only in arthritis but also in diabetes, athero-
sclerosis, tumors, and transplantation (42–44). Further under-
standing of the cellular and molecular conditions that facilitate 
pathogenic versus regulatory immune responses to Hsp65 would 
pave the way for harnessing the immunomodulatory attributes of 
Hsp65 for therapeutic purposes in human diseases, as exemplified 
by the use of p277 of self-Hsp60 in human type 1 diabetes (45). 
This in turn would add novel agents to the therapeutic arsenal to 
control a variety of immune-mediated diseases.
In brief, the major new conceptual developments emerging 
from studies on immunity to Hsp65 in AA can be summarized as 
follows: (a) foreign–self antigen cross-reactivity, also referred to 
as “molecular mimicry,” has generally been viewed as a mecha-
nism of induction of autoimmunity; however, studies in AA 
have shown that such a cross-reactivity (e.g., B256 and BCTD) 
can be immunoregulatory in nature; (b) most times, foreign–self 
cross-reactivity is limited to the corresponding homologous 
regions of the two proteins; in AA, a pathogenic epitope (B180/
B177) can recruit a subset of T cells potentially reactive against 
a protective self-epitope (R465), thus elaborating a novel aspect 
of such cross-reactivity; (c) immune response to a self-antigen, 
which signifies a break in self-tolerance, has been the cornerstone 
of mechanisms to explain the initiation of autoimmunity; stud-
ies in AA have revealed that deliberate priming of self-reactive 
T cells using self-Hsp65 (human Hsp60 or rat Hsp65) as the 
immunogen, can effectively suppress arthritis; furthermore, the 
spontaneous emergence of anti-self T cell response during the 
course of AA can contribute to natural regression of autoim-
mune inflammation; (d) antibodies to foreign/self antigens are 
known to serve as mediators of immune pathology in a variety 
of autoimmune diseases; in AA, antibodies to Hsp65 have been 
shown to be protective against arthritis; and (e) previous work on 
peptide-based therapy of AA involved APL of peptides of foreign 
Hsp65 (Bhsp65); recent studies highlight that APL of self-Hsp60 
also can serve as potent immunomodulatory agents.
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